Newsletter-Jan-2025
Stemnovate had an exceptional year in 2024, marked by significant achievements that we can all be proud of. We are pioneering a research platform dedicated to addressing rare diseases in children, a milestone that reflects our collective commitment and progress in this vital area.
Developing treatments for rare diseases is particularly challenging due to several factors, the small patient population and the late diagnoses resulting from a lack of early screening present considerable obstacles. Furthermore, the regulatory complexities of recruiting young children for research studies and clinical trials add another layer of difficulty.
Our mission's core is a patient-centric approach that addresses the numerous challenges in rare disease research. This approach showcases our dedication to patients and their families and integrates them as vital contributors to our journey.
We remain committed to providing a user-friendly process for volunteering in our studies. With a compliant ethical framework, we work closely with parents to ensure their comfort and understanding. Read more
Our partnerships with leading pharmaceutical companies are crucial in turning early research findings into commercially available treatments for conditions such as mitochondrial diseases as well as liver and neurodegenerative disorders.
Stemnovate is also committed to reducing animal testing by providing next-generation cell models for research. These models not only enhance animal health and welfare but also pave the way for developing advanced medicines for humans. Read more
Thanks to our incredible team and the invaluable contributions of our academic partners, Stemnovate has successfully advanced challenging research projects for academia and industry. We are thrilled to announce that our three academic partners have PhD studentships awarded to work with Stemnovate. Read more
We wish everyone a splendid start to the year 2025!
Stemnovate Limited, Maia Building (270), Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT, United Kingdom, +44 (0)1223830192
Redefining drug discovery through data ®
© 2023 STEMNOVATE LIMITED